{
    "ticker": "ARQT",
    "name": "ArQule, Inc.",
    "description": "ArQule, Inc. is a biotechnology company dedicated to the discovery and development of targeted therapies for cancer and other serious diseases. Founded in 1993 and based in Burlington, Massachusetts, ArQule focuses on advancing innovative drug candidates that leverage its proprietary research platform. The company has made significant strides in the field of oncology, particularly with its lead product candidate, which is designed to inhibit specific pathways involved in tumor growth. ArQule's commitment to precision medicine is evident in its strategic collaborations with major pharmaceutical companies, enabling it to enhance its research capabilities and accelerate the development of its product pipeline. With a strong emphasis on scientific innovation, ArQule aims to transform the treatment landscape for patients by providing therapies that are not only effective but also tailored to individual patient profiles. The company's ongoing clinical trials and research initiatives underscore its dedication to improving patient outcomes and advancing the field of cancer therapeutics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Burlington, Massachusetts, USA",
    "founded": "1993",
    "website": "https://www.arqule.com",
    "ceo": "Paolo Pucci",
    "social_media": {
        "twitter": "https://twitter.com/ArQuleInc",
        "linkedin": "https://www.linkedin.com/company/arq-inc/"
    },
    "investor_relations": "https://investors.arqule.com",
    "key_executives": [
        {
            "name": "Paolo Pucci",
            "position": "CEO"
        },
        {
            "name": "Rafael Amado",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "ARQ 197",
                "ARQ 751"
            ]
        }
    ],
    "seo": {
        "meta_title": "ArQule, Inc. | Targeted Cancer Therapies",
        "meta_description": "Explore ArQule, Inc., a leader in biotechnology focused on developing targeted therapies for cancer. Learn about our innovative drug candidates and commitment to precision medicine.",
        "keywords": [
            "ArQule",
            "Biotechnology",
            "Cancer Therapies",
            "Oncology",
            "Targeted Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is ArQule known for?",
            "answer": "ArQule is known for its focus on the discovery and development of targeted therapies for cancer."
        },
        {
            "question": "Who is the CEO of ArQule?",
            "answer": "Paolo Pucci is the CEO of ArQule, Inc."
        },
        {
            "question": "Where is ArQule headquartered?",
            "answer": "ArQule is headquartered in Burlington, Massachusetts, USA."
        },
        {
            "question": "What are ArQule's main products?",
            "answer": "ArQule's main products include ARQ 197 and ARQ 751, which are in development for oncology."
        },
        {
            "question": "When was ArQule founded?",
            "answer": "ArQule was founded in 1993."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "AZN",
        "REGN"
    ],
    "related_stocks": [
        "GILD",
        "JNJ",
        "MRK",
        "PFE"
    ]
}